Effects of dehydroepiandrosterone on quality of life in premenopausal women with rheumatoid arthritis: A preliminary randomized clinical trial.

Abstract

Chronic inflammation and subsequent use of glucocorticoids can lead to relative adrenocortical insufficiency in patients with rheumatoid arthritis (RA). Previously, adrenocortical hormone, dehydroepiandrosterone (DHEA) was shown as a potential therapy for autoimmune disorders. However, data regarding effects of DHEA in RA are limited. The aim of this study was to investigate the effects of DHEA on quality of life (QOL) in premenopausal rheumatoid arthritis patients. In this randomized double blinded, controlled trial 46 premenopausal rheumatoid arthritis patients were assigned to receive 50mg/d DHEA (23 patients) or placebo (23 patients) for 12weeks. Disease Activity Score of 28 joints - erythrocyte sedimentation rate (DAS28-ESR) questionnaire, visual analog score and swollen and tender joint counts (both 0-28) were used for assessment of disease activity. Persian-validated World Health Organization Quality of Life Brief version (WHOQOL BREF) questionnaire was used to assess quality of life. In comparison to the control group more improvement in QOL (P=.025) and environment health (P=.001) was observed in the DHEA group. After adjustment for age and disease duration DHEA was associated with more improvement in QOL (P=.01), psychological (P=.02) and physical health (P=.03). A trend toward a decrease in ESR was observed in DHEA group (P=.06). DAS was improved in both groups; however, there was no significant change in DAS28 between groups (P=.88). Frequency of adverse events albeit minor was similar in both groups. Our study supports a slightly superior effect of DHEA over placebo to improve QOL in premenopausal female patients with rheumatoid arthritis. We did not find improvement in DAS in the DHEA group over placebo.